Pdt Partners Raised Its Holding in Diplomat Pharmacy (DPLO) as Shares Rose; Alnylam Pharmaceuticals (ALNY) Holder Point72 Asset Management LP Has Increased Holding

February 15, 2018 - By Adrian Erickson

Peter Muller increased its stake in Diplomat Pharmacy Inc (DPLO) by 105.25% based on its latest 2017Q3 regulatory filing with the SEC. Pdt Partners Llc bought 116,606 shares as the company’s stock rose 20.96% with the market. The hedge fund run by Peter Muller held 227,393 shares of the health care company at the end of 2017Q3, valued at $4.71M, up from 110,787 at the end of the previous reported quarter. Pdt Partners Llc who had been investing in Diplomat Pharmacy Inc for a number of months, seems to be bullish on the $1.76 billion market cap company. The stock increased 3.16% or $0.74 during the last trading session, reaching $24.16. About 1.39 million shares traded or 53.58% up from the average. Diplomat Pharmacy, Inc. (NYSE:DPLO) has declined 40.48% since February 15, 2017 and is downtrending. It has underperformed by 57.18% the S&P500.

Steve Cohen increased its stake in Alnylam Pharmaceuticals Inc (ALNY) by 70% based on its latest 2017Q3 regulatory filing with the SEC. Point72 Asset Management Lp bought 35,000 shares as the company’s stock rose 48.45% with the market. The hedge fund run by Steve Cohen held 85,000 shares of the health care company at the end of 2017Q3, valued at $9.99 million, up from 50,000 at the end of the previous reported quarter. Point72 Asset Management Lp who had been investing in Alnylam Pharmaceuticals Inc for a number of months, seems to be bullish on the $11.96B market cap company. The stock increased 0.60% or $0.72 during the last trading session, reaching $119.98. About 498,513 shares traded. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has risen 33.54% since February 15, 2017 and is uptrending. It has outperformed by 16.84% the S&P500.

Among 23 analysts covering Alnylam Pharmaceuticals (NASDAQ:ALNY), 17 have Buy rating, 1 Sell and 5 Hold. Therefore 74% are positive. Alnylam Pharmaceuticals had 96 analyst reports since August 7, 2015 according to SRatingsIntel. Jefferies maintained Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) on Friday, February 9 with “Buy” rating. Nomura initiated the stock with “Sell” rating in Friday, September 15 report. JP Morgan downgraded the stock to “Neutral” rating in Friday, August 7 report. The stock has “Buy” rating by B. Riley & Co on Wednesday, November 8. Cowen & Co maintained the shares of ALNY in report on Monday, June 26 with “Buy” rating. The firm has “Buy” rating by Bernstein given on Thursday, September 21. The stock of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has “Buy” rating given on Monday, June 26 by Needham. BMO Capital Markets maintained the stock with “Outperform” rating in Friday, September 8 report. The rating was maintained by Cowen & Co with “Buy” on Friday, August 4. The firm has “Outperform” rating by Credit Suisse given on Thursday, October 6.

Point72 Asset Management Lp, which manages about $22.41B US Long portfolio, decreased its stake in Himax Technologies Inc (NASDAQ:HIMX) by 55,500 shares to 74,000 shares, valued at $809,000 in 2017Q3, according to the filing. It also reduced its holding in Oil Sts Intl Inc (NYSE:OIS) by 101,500 shares in the quarter, leaving it with 160,300 shares, and cut its stake in Wal (NYSE:WMT).

Since September 20, 2017, it had 0 insider buys, and 3 insider sales for $23.18 million activity. On Wednesday, September 20 the insider Greene Barry E sold $7.68M.

Investors sentiment decreased to 0.92 in Q3 2017. Its down 0.60, from 1.52 in 2017Q2. It is negative, as 30 investors sold ALNY shares while 73 reduced holdings. 40 funds opened positions while 55 raised stakes. 86.02 million shares or 0.72% more from 85.40 million shares in 2017Q2 were reported. 134,688 were accumulated by Teachers Retirement Of The State Of Kentucky. Credit Suisse Ag stated it has 0.02% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Sg Americas Securities Ltd Company reported 0% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Massachusetts-based Tekla Cap Ltd Llc has invested 0.48% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Fic has invested 6.74% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Two Sigma Ltd Limited Liability Company accumulated 0.02% or 2,039 shares. Legal General Gp Public Limited Co owns 32,360 shares. Benjamin F Edwards & has invested 0% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). 1.08 million were reported by Orbimed Advisors Lc. New York-based 12 West Mgmt LP has invested 11.5% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Goldman Sachs has invested 0.05% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Ny State Common Retirement Fund has 216,488 shares. Axa accumulated 40,316 shares. Fmr Ltd Liability accumulated 0.2% or 13.76M shares. Parametric Assocs Ltd Co holds 63,312 shares or 0.01% of its portfolio.

Among 14 analysts covering Diplomat Pharmacy (NYSE:DPLO), 5 have Buy rating, 0 Sell and 9 Hold. Therefore 36% are positive. Diplomat Pharmacy had 39 analyst reports since August 4, 2015 according to SRatingsIntel. Bank of America upgraded the stock to “Neutral” rating in Wednesday, October 14 report. The rating was maintained by Needham on Tuesday, September 12 with “Buy”. The company was upgraded on Monday, December 11 by Leerink Swann. The firm has “Underperform” rating given on Wednesday, November 23 by Credit Suisse. The stock of Diplomat Pharmacy, Inc. (NYSE:DPLO) earned “Mkt Perform” rating by Leerink Swann on Thursday, November 3. On Wednesday, January 24 the stock rating was maintained by Mizuho with “Hold”. The firm has “Market Perform” rating given on Thursday, November 3 by Raymond James. The firm has “Market Perform” rating by Cowen & Co given on Friday, June 24. The rating was maintained by Mizuho on Wednesday, May 11 with “Neutral”. On Wednesday, October 21 the stock rating was initiated by UBS with “Buy”.

Pdt Partners Llc, which manages about $4.99B and $3.02B US Long portfolio, decreased its stake in Hp Inc by 294,344 shares to 372,123 shares, valued at $7.43M in 2017Q3, according to the filing. It also reduced its holding in Manulife Finl Corp (NYSE:MFC) by 46,682 shares in the quarter, leaving it with 71,465 shares, and cut its stake in Innoviva Inc.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: